Vidanga

Vidanga (Embelia ribes Burm.f.): A Comprehensive Reference

1. Identity and Botanical Classification

1.1 Scientific Name, Taxonomy, and Synonymy

Embelia ribes Burm.f., also known as Vidanga or Baibidanga in Ayurvedic medicine, has been an essential ingredient in a variety of Ayurvedic compositions. Embelia ribes is classified within the kingdom Plantae, phylum Tracheophyta, class Magnoliopsida, order Ericales, family Primulaceae, genus Embelia, and species E. ribes. Note that the species was historically and widely assigned to the family Myrsinaceae; under modern APG IV classification, Myrsinaceae has been subsumed within the broader family Primulaceae.

E. ribes was first described by Nicolaus Laurens Burman filius in his 1768 work Flora Indica. Accepted synonyms for E. ribes include Antidesma ribes (Burm.f.) Raeusch. and Ribesiodes ribes (Burm.f.) Kuntze, reflecting historical nomenclatural variations. The genus Embelia consists of approximately 130 species of mostly climbing shrubs distributed across tropical and subtropical regions.

1.2 Common Names

It is commonly known as false black pepper or Vidanga. Additional vernacular names documented across traditional medicine systems include:

• Sanskrit/Ayurveda: Vidanga, Vayavidanga, Baibidanga
• Unani: Baobarang; Siddha: Vaivilangam; Tibetan: Byi dan ga; Homeopathic: Embelia ribes
• Hindi: Baberang, Vavding

1.3 Botanical Description and Natural Habitat

A straggling, large scandent shrub with long branches and slender, flexible internodes; the plant is almost a climber. The bark of the species is studded with lenticels, with a whitish-gray stem and a mature girth of 45–72 cm. Leaves are elliptic, coriaceous, 6–14 cm long and 2–4 cm broad, lanceolate, alternating, acuminate entire, perfectly glabrous. Flowers are small, greenish-yellow, numerous in lax panicled racemes, with a flowering time of February. Fruits are berry, globular, 2.4–4.0 mm in diameter with a warty surface, smooth, and succulent; the colour of the dried fruit is dull black and rarely dull red, resembling a peppercorn.

It is a plant widely distributed in Cambodia, south China, India, Laos, Malaysia, Sri Lanka, Thailand, Vietnam, and elsewhere. Within India, E. ribes grows in semi-evergreen and deciduous forests at an altitude of 1,500 m, found in the central and lower Himalayas, Arunachal Pradesh, Assam, Bengal, Orissa, Andhra Pradesh, and Madhya Pradesh.

1.4 Pharmacopoeial Status

Vidanga was first listed as an official medicament in the Indian Pharmacopoeia in 1966, with the botanical origin being limited to the fruits of E. ribes. Since then, the dried berries of E. ribes fruits belonging to the Myrsinaceae family have been largely regarded as the official source.

1.5 Conservation Status

Due to overexploitation of this plant, it is reported in the Red List Data Book as vulnerable. Embelia ribes is not globally assessed by the IUCN Red List and has been evaluated at state levels in India through CAMP workshops, with varying threat statuses. At the state level, it holds Vulnerable status in Karnataka, Nagaland, Orissa, and Sikkim; Near Threatened in Arunachal Pradesh and Kerala; and Critically Endangered in Andhra Pradesh, reflecting regional variations in threat levels. The species is not listed under CITES appendices, though its export from India is prohibited under the Directorate General of Foreign Trade (DGFT) negative list to regulate trade.

2. Common Forms and Preparations

Vidanga (dried ripe fruits of Embelia ribes) is a popular Ayurvedic herbal medicinal product used traditionally in India as an anthelmintic, carminative, and stimulant. The root, berries, and leaves of Embelia ribes are used in herbal formulas.

Documented traditional and modern preparation forms include:

• Various forms used in Ayurveda include churna (powder), asava and arishta (fermented liquid preparations), lauha (iron-based preparations), and taila (medicated oils).
• Vidanga is used in the preparation of panchanimbadivati, sanjivanivati, and chandraprabhavati.
• Commercial Ayurvedic formulations containing Vidanga include Ardrakakhandavaleha, Eranda paka, Krimighna kashaya churna, Vidangadi churna, and Taramandura guda.
• Vaibidang (Embelia ribes) is crucial in Ayurvedic formulations, used in approximately 75 preparations.

In modern scientific research, preparations investigated include ethanolic extracts, aqueous extracts, methanolic extracts, and isolated embelin. The hydrophobic nature of embelin leads to poor absorption and limits its therapeutic potential; researchers have explored nanocarriers used as delivery systems for embelin, including polymeric nanoparticles, liposomes, nanostructured lipid carriers, micelles, nanoemulsions, and metallic nanoparticles.

3. Traditional and Historical Use

3.1 Ayurveda

Embelia ribes Burm.f., also known as Vidanga, is one of the oldest herbs in Indian traditional medicine. It has a long history of use in the Ayurvedic system of medicine in various forms including churna, asava, aristha, lauha, bati, and taila.

The three ancient Indian Ayurvedic books — Charaka Samhita, Sushruta Samhita, and Ashtanga Hridayam — all reference Vidanga. References to Embelia ribes date back to classical Ayurvedic texts like the Charaka Samhita (circa 2nd century CE) and Sushruta Samhita, where Vidanga is praised under the category of anti-krimi (anti-parasitic) remedies.

Historical texts such as the Charaka Samhita and Sushruta Samhita (circa 600 BCE–200 CE) reference Vidanga for deworming and enhancing digestive fire (Agni), often in combination with other herbs to alleviate abdominal bloating and constipation. Ancient healers recommended Vidanga phala (fruit) powder for intestinal worms and pinworms, believing its tikta-kashaya (bitter-astringent) taste would repel toxins and parasites.

In Ayurveda, Embelia ribes is classified as having Katu (pungent) and Tikta (bitter) rasa, along with Ushna (hot) virya and Kaphavata shamaka properties. It is primarily employed as an anthelmintic for treating Krimi (intestinal worms and parasites), Ajeerna (indigestion and dyspepsia), Medoroga (obesity and fat accumulation), and Prameha (urinary disorders akin to diabetes).

The ancient Ayurvedic physician Sushruta described that the fruit of the E. ribes plant possesses anthelmintic properties and is used as a tonic along with licorice root, which prevents aging and helps in strengthening the body.

In Ayurveda, it is used to cure skin diseases, abdominal pains, flatulence, worms, mental disorders, tumors, bronchitis, jaundice, cardiac disorders, and is used as a brain tonic.

Among herbal supplements recommended for the management of obesity in Ayurveda is Vidanga (Embelia ribes). Vidanga, combined with Shunthi, Yava-Kshara, and ash powder of black iron mixed with honey and the powder of barley and Amalaki, is described as an excellent formulation for obesity.

3.2 Other Traditional Medicine Systems

Embelia ribes Burm is extensively used in Indian, folk, homeopathic, Tibetan, Unani, and Siddha traditional medicinal systems for treating various ailments like chronic inflammatory disorders, heart and urinary conditions, snake and insect bites, and tumor.

The plant is highly esteemed in the Unani system of medicine as a powerful anthelmintic. In the Siddha tradition, it is known as Vaivilangam and the dried fruits are used similarly to Ayurvedic applications. In medieval herbal treatises such as Bhavaprakasha, Vidanga is described as manjari rakta chitra (cluster of red spots), symbolizing its rich color.

The dried fruit is considered anthelmintic, astringent, carminative, alterative, and stimulant. Dried fruits were traditionally used as anthelmintic, astringent, alterative, and tonic; in ascariasis, scorpion sting, and snake bite. The decoction was considered useful in fevers and diseases of the chest and skin. Infusion of the roots was used for cough and diarrhoea.

4. Key Constituents and Phytochemistry

4.1 Primary Active Constituent: Embelin

Embelin is chemically known as 2,5-dihydroxy-3-undecyl-1,4-benzoquinone, which is the major active constituent of the fruits of Embelia ribes Burm (family Myrsinaceae), commonly known as "False Black Pepper." Embelin, a natural para-benzoquinone product, is derived from plants of the Embelia genus, particularly Embelia ribes Burm.f. A staple in traditional medicinal formulations for centuries, embelin's pharmacological actions are attributed to the hydroxyl benzoquinone present in its structure.

The concentration of embelin in the seeds has been reported at 2.5–3.1% in some analyses. Methanolic extract of berries exhibited the highest total phenolic content, while ethanolic extract showed the highest total flavonoid content.

4.2 Secondary Constituents

The main chemical constituent of E. ribes is embelin, and other chemical constituents are volatile oils, tannins, christembine, resinol, embeliol, embelinol, quercitol, vilangin, potassium embelate, aryl-substituted benzoxadiazine, 5-O-ethylembelin, 5-O-methylembelin (derivatives), 2-hydroxy-5-substituted-3-undecylcyclohexa-2,5-diene-1,4-diones (derivatives), and phenolic acids like caffeic acid.

Among the phytocompounds with the greatest potential are embelin, vilangin, embeliaflavosides, and embelialkylresorcinols. Phytochemical investigation of the seeds of Embelia ribes resulted in the isolation of three new compounds identified as embelinol (1), embeliaribyl ester (2), and embeliol (3), along with the known compound embelin (4).

5. Mechanisms of Action

5.1 XIAP Inhibition and Apoptosis Pathways

Embelin, recognized as a non-peptidic, cell-permeable small inhibitor of the X-linked inhibitor of apoptosis protein (XIAP), has garnered significant attention for its anticancer activity. It demonstrates various anticancer mechanisms, such as apoptosis induction, cell cycle arrest, and autophagy, in different cancer types. Additionally, embelin modulates several signal transduction pathways, including NF-κB, PI3Kinase/AKT, and STAT3, effectively inhibiting the proliferation of diverse cancer cell lines.

A thorough computational-database screening revealed that, structurally, embelin could be characterized as a pharmacological inhibitor of XIAP (X chromosome–linked inhibitor-of-apoptosis protein). The anticancer activity of embelin is mediated by inhibition of X-linked anti-apoptotic protein (XIAP), NF-kappaB, PCAF, TACE, TNF-α, and other cytokines.

5.2 Anti-inflammatory Mechanisms

Several studies have shown that the anti-inflammatory activity of embelin is mediated by reduction in TNF-α. TNF-α is synthesized as a membrane-anchored protein (pro-TNF-α); the soluble component is released into the extracellular space by the action of a protease called TNF-α converting enzyme (TACE). Embelin has been shown to have in vivo anti-inflammatory activity in both acute and chronic models of psoriasis and inflammatory skin diseases. It has been reported to reduce TNF-α production in both LPS- and TPA-induced inflammation.

5.3 MAP Kinase and Oxidative Stress Signaling

Treatment of A549 lung cancer cells with embelin resulted in the enhancement of phospho-p38 and phospho-JNK levels as early as 4 hours; pretreatment of cells with specific inhibitors of p38 and JNK abrogated embelin-induced caspase-3 activation. Reactive oxygen species (ROS) play a crucial role in embelin-induced alterations in MAP kinase phosphorylation and apoptosis.

5.4 Anthelmintic Mechanism

Embelin has shown notable anthelmintic efficacy in several research investigations. Studies have demonstrated that embelin, in both its crude hydroalcoholic extract form and as a diammonium salt, possesses anthelmintic properties against intestinal parasites such as the dwarf tapeworm and hookworm, with significant rates of parasite clearance in both in vivo and in vitro models. Research on the seeds of E. ribes has also shown strong anthelmintic effects of aqueous and alcoholic extracts against parasites such as Haemonchus contortus in sheep.

5.5 Antidiabetic Mechanisms

The ethanolic extract of Embelia ribes significantly decreased the pancreatic thiobarbituric acid-reactive substances (TBARS) levels and significantly increased superoxide dismutase, catalase, and glutathione levels compared to levels in pancreatic tissue of diabetic rats. The study concludes that Embelia ribes enhances the antioxidant defense against reactive oxygen species produced under hyperglycemic conditions, and this protects β-cells against loss, exhibiting antidiabetic properties.

5.6 Neuroprotective and CNS Mechanisms

Embelin, the main active constituent of Embelia ribes, has been reported to possess various pharmacological actions, mainly anti-inflammatory, antioxidant, anticonvulsant, and neuroprotective.

5.7 Pharmacokinetics and Bioavailability

The oral bioavailability of embelin was found to be 30.2 ± 11.9% in rats. This study provided information about the pharmacokinetics and oral bioavailability of embelin, which is useful to assess its clinical efficacy and safety and to promote further development. The hydrophobic nature of embelin leads to poor absorption and limits its therapeutic potential, which is a central challenge in its development as a pharmaceutical agent.

6. Scientific Evidence by Area of Use

6.1 Anthelmintic Activity

Evidence strength: Preclinical (in vitro and animal); limited human data

Embelin, a benzoquinone-derivative isolated from Embelia ribes, when tested for its antibacterial potential exhibited significant inhibition against five and moderate activity against three strains of the 12 bacteria tested.

For anthelmintic activity specifically, in vivo cestocidal activity of the crude hydroalcoholic extract of the related species E. schimperi showed 100% parasite clearance at 1000 mg/kg, while the diammonium salt of embelin showed 85.3% parasite clearance at 750 mg/kg. The in vitro anthelmintic activity study revealed that the LC₅₀ value of the crude extract and albendazole were 228.7 and 51.33 μg/mL, respectively. The results clearly indicated that the hydroalcoholic extract and the diammonium salt of the isolated compound embelin had anthelmintic activity against hookworm larvae in vitro and H. nana in vivo.

Research on the seeds of E. ribes has also demonstrated strong anthelmintic effects of aqueous and alcoholic extracts against parasites such as Haemonchus contortus in sheep. No controlled human clinical trials on embelin or E. ribes extracts as anthelmintics have been published as of the current literature review; available evidence is preclinical.

6.2 Anticancer Activity

Evidence strength: Preclinical (in vitro and animal); no human clinical trials reported

The chemopreventive activities of embelin have been demonstrated by numerous studies. Embelin has been shown to inhibit N-nitrosodiethylamine-initiated and phenobarbital-promoted hepatocarcinogenesis. In another study, embelin inhibited 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis. In one study, the anti-tumour activity of embelin was attributed to its ability to bind to and inhibit XIAP.

Embelin causes a dose-dependent suppression of proliferation in leukemic cell lines K562 and U937. Embelin-mediated inhibition of proliferation correlates with induction of apoptosis. Furthermore, embelin treatment causes loss of mitochondrial membrane potential and release of cytochrome c, resulting in subsequent activation of caspase-3. Embelin treatment of leukemic cells also results in a decrease of constitutive phosphorylation/activation of AKT and downregulation of XIAP.

Embelin has also been reported to inhibit NF-κB activation and STAT3 activation in cancer cells. Drug resistance of non-small cell lung cancer cells (NSCLC) caused by overexpression of XIAP was inhibited by embelin with an efficacy similar to XIAP siRNA.

A review of the literature revealed a lack of translational research, and not a single study was found in humans for embelin, which identifies a further pathway to explore in clinical trials for its safety and efficacy. All anticancer findings are derived from cell lines and animal experiments and cannot be extrapolated to clinical use.

6.3 Antidiabetic Activity

Evidence strength: Preclinical (animal studies); systematic review supports preclinical findings; no human trials

A study was undertaken to investigate the modulatory effect of 6 weeks' chronic oral administration of E. ribes ethanolic extract on diabetes mellitus induced by streptozotocin (STZ) with special reference to changes in glucose levels, glycated haemoglobin status, and cardiac toxicity. Forty days of oral feeding of the extract (100 mg/kg and 200 mg/kg) to diabetic rats resulted in significant decrease in blood glucose, blood glycosylated haemoglobin, serum lactate dehydrogenase, and creatine kinase, and an increase in blood glutathione levels.

Embelin (25 and 50 mg/kg b.w.) administered orally to alloxan-induced diabetic rats for 21 days caused a significant reduction in fasting serum blood glucose levels and significant improvement in body weights. Significant antidiabetic effects were obtained as evident from the restoration of biochemical parameters altered by alloxan towards normal.

A systematic review and meta-analysis (published 2017 in Biomedicine & Pharmacotherapy) evaluated the totality of preclinical evidence: meta-analysis findings reported considerable restoration of insulin, lipid profile, haemodynamic parameters, serum and oxidative stress markers. The derivatives of embelin — 6-bromoembelin and vilangin — also improved diabetic condition. Treatments also ameliorated body weight changes due to diabetes. The systematic review and meta-analysis supports scientific evidence for the antidiabetic activity of E. ribes/embelin/derivatives of embelin. However, further research is warranted in clinical trials to validate the present findings.

6.4 Anti-inflammatory and Analgesic Activity

Evidence strength: Preclinical (in vitro and animal); no human trials

Several studies have shown that the anti-inflammatory activity of embelin is mediated by reduction in TNF-α. Embelin, a quinone derivative, is found in the fruits of Embelia ribes Burm (Myrsinaceae) and has been shown to have a variety of therapeutic potentials including anthelmintic, anti-tumor, anti-diabetic, anti-bacterial, and anti-inflammation. Based on molecular dynamics and experimental data, embelin has been proposed as a natural anti-inflammatory and anticancer drug.

6.5 Antifertility Activity

Evidence strength: Preclinical (animal studies, predominantly rats); no human trials

Antifertility investigations for embelin date to the early 1970s through the 1980s, published in journals including Indian Journal of Experimental Biology and Planta Medica. Kholkute et al. (1978) administered powdered berries of E. ribes in the diet at a dose level of 2 and 4 g/day and observed 62% antifertility activity with a dose of 4 g/day. Embelin at 50–100 mg/kg, p.o., in rats (day 1–7 of pregnancy) exhibited 85.71% anti-implantation activity, with significant antiestrogenic and progestational properties.

Oral doses (15, 30, 60, and 120 mg/kg) of embelin, when administered (day 1–5 of pregnancy) in proven fertile female rats, exhibited 55.55–83.33% anti-implantation effect. In conclusion, both Embelia ribes and embelin possess significant antifertility activity in female rats, whereas embelin also possesses antispermatogenic activity in male rats.

This body of evidence is exclusively derived from animal models. No human clinical trials of antifertility activity have been published.

6.6 Antibacterial Activity

Evidence strength: In vitro; no human clinical trials

Embelin, a benzoquinone-derivative isolated from Embelia ribes, when tested for its antibacterial potential exhibited significant inhibition against five and moderate activity against three strains of the 12 bacteria tested. These findings are limited to in vitro experiments and have not been validated in controlled human studies.

6.7 Neuroprotective and CNS Activity

Evidence strength: Preclinical (animal models); no human trials

A systematic review published in Frontiers in Pharmacology (2017) examined the CNS-related evidence for embelin. Embelin, the main active constituent of Embelia ribes, has been reported to possess various pharmacological actions, mainly anti-inflammatory, antioxidant, anticonvulsant, and neuroprotective. The aim of one study was to evaluate the neuroprotective effect of embelin against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats. Adult Wistar rats were pretreated with vehicle/embelin (10 and 20 mg/kg p.o.) for 7 days, then co-treated with 3-NP for a further 7 days. At the end of treatment, animals were evaluated for behavioral alterations and brain homogenates were used for estimation of oxidative stress parameters.

Among the many promising pharmacological effects demonstrated by the essential oils, extracts, and isolated chemical constituents were those relevant to central nervous system (CNS) disease. However, all such evidence is preclinical.

6.8 Antiobesity Activity

Evidence strength: Preclinical; no human trials

Embelia ribes is a plant that has been studied for its potential antiobesity effects, particularly in the context of high-fat diet-induced obesity in experimental models. Embelin, an active component of the fruits of Embelia ribes, has been demonstrated to possess a broad-spectrum of therapeutic properties including anti-obesity. No human clinical trials exist.

6.9 Cardioprotective Activity

Evidence strength: Preclinical (animal studies); no human trials

The literature on embelin specifically covers its cardioprotective properties alongside antidiabetic, neuroprotective, anti-inflammatory, antiviral, antibacterial, anti-oxidant, wound healing, antifertility, analgesic, and anticancer properties. Cardioprotective evidence comes from animal models of isoproterenol-induced myocardial injury, and no human data are available.

6.10 Hepatoprotective Activity

Evidence strength: Preclinical (animal studies); no human trials

E. ribes, commonly known as Vedanga, is one such traditional medicine of plant origin, reported to be useful in the treatment of jaundice. Preclinical research has investigated the hepatoprotective properties of E. ribes in D-galactosamine-induced hepatotoxic rats, but this has not been extended to human clinical studies.

7. Body Systems and Health Areas

Based on the scientific and traditional literature, the following body systems and health areas are associated with Vidanga:

• Gastrointestinal system: Traditionally used as an appetizer, carminative, laxative, anthelmintic, and in liver diseases.
• Metabolic / Endocrine system: Antidiabetic, antihyperlipidemic, and antiobesity activity are the subject of multiple preclinical studies.
• Immune / Inflammatory system: Anti-inflammatory and antioxidant properties documented in preclinical research.
• Central nervous system: The literature covers neuroprotective, anticonvulsant, and antidepressant properties.
• Oncology (preclinical only): Embelin demonstrates anticancer mechanisms including apoptosis induction, cell cycle arrest, and autophagy in different cancer types, and modulates signal transduction pathways including NF-κB, PI3Kinase/AKT, and STAT3.
• Reproductive system: Documented antifertility and anti-implantation activity in animal models.
• Skin and integument: Traditionally used for skin diseases and wound healing; wound healing activity has been among the pharmacological effects studied.
• Cardiovascular system: Cardioprotective properties have been studied in preclinical models.
• Hepatic system: Hepatoprotective activity has been explored in animal models; traditional use in jaundice is documented.

8. Dosage Forms and Reported Dosages

The following dosages appear specifically in the peer-reviewed research cited in this article and are reported as used in preclinical (animal) research only, unless otherwise indicated. No approved human therapeutic doses are established in the reviewed literature.

• In a rat model of streptozotocin-induced diabetes: ethanolic extract of Embelia ribes at 100 mg/kg and 200 mg/kg orally for 40 days.
• In a rat model of Huntington's disease: embelin at 10 and 20 mg/kg p.o. for 7 days pretreatment, followed by co-treatment for a further 7 days.
• In an alloxan-induced diabetic rat model: embelin at 25 and 50 mg/kg body weight, administered orally for 21 days.
• Anti-implantation studies in rats: embelin at 50–100 mg/kg, p.o., on days 1–7 of pregnancy.
• Additional anti-implantation rat studies used oral doses of 15, 30, 60, and 120 mg/kg on days 1–5 of pregnancy.
• In vivo anthelmintic study: hydroalcoholic extract at 1000 mg/kg; diammonium salt of embelin at 750 mg/kg.
• Subacute toxicity study: repeated administration of embelin at 10 mg/kg dose was found to be safe in rats.

In traditional Ayurvedic practice, the reported dosage for churna (powder) is described in classical texts, though these are not standardized against embelin content or validated in controlled human trials.

9. Safety, Toxicology, and Notable Interactions

9.1 Acute Toxicity

Embelin has been studied for its safety and toxicity profile in rodents and non-rodents. It is reported that embelin is safe up to 3 g/kg orally when tested in rodents after acute exposure. Embelin is described as a non-toxic compound and is well tolerated up to a dose of 3 g/kg body weight.

A study on the related species Embelia schimperi (which contains the same active compound) found that in the acute toxicity study, no prominent signs of toxicity and mortality were recorded among the experimental animals at the highest administered dose, and the LD₅₀ of the plant was found to be higher than 5000 mg/kg.

9.2 Subacute and Repeat-Dose Toxicity

Another report on subacute toxicity after repeated administration of embelin at 10 mg/kg dose found it to be safe in rats.

9.3 Antifertility Concerns and Reproductive Safety

Both Embelia ribes and embelin possess significant antifertility activity in female rats, and embelin also possesses antispermatogenic activity in male rats. These findings constitute a specific and important safety signal: the plant and its principal constituent have been shown in multiple animal studies to interfere with implantation and male fertility. This body of evidence makes the use of Embelia ribes or embelin-containing preparations a matter of significant concern during pregnancy or when fertility is desired.

9.4 Bioavailability and Formulation Considerations

The hydrophobic nature of embelin leads to poor absorption and limits its therapeutic potential. The oral bioavailability of embelin has been measured at 30.2 ± 11.9% in rats. This pharmacokinetic limitation is relevant to any assessment of effective dosing in humans.

9.5 Conservation and Supply Chain Safety

The primary threats to Embelia ribes include unsustainable wild collection driven by high demand in the Ayurvedic industry. Regeneration of the crop is poor due to overexploitation, diminishing forest area, dormant seeds, abortive embryos, and hard seed coat. These factors raise practical concerns about adulteration and quality consistency in commercially available preparations.

9.6 Absence of Human Clinical Safety Data

A review of the literature revealed that there is a lack of translational research, and not a single study was found in humans for embelin, which gives embelin a further way to be explored in clinical trials for its safety and efficacy. The absence of controlled human trials means that the safety profile of Embelia ribes preparations in human populations — including drug interactions, organ toxicity at therapeutic doses, and long-term effects — is not established from clinical evidence.

References

• Ghorbani Nohooji M, et al. "Reviewing the Traditional/Modern Uses, Phytochemistry, Essential Oils/Extracts and Pharmacology of Embelia ribes Burm." Antioxidants 11(7):1359 (2022) — PMC9311956
• Dheeraj T, et al. "Embelin: A multifaceted anticancer agent with translational potential in targeting tumor progression and metastasis." PMC10792175
• Bhatt H, et al. "Embelin inhibits TNF-α converting enzyme and cancer cell metastasis: molecular dynamics and experimental evidence." BMC Cancer 14:775 (2014) — PMC4210574
• Koyama S, et al. "Activation of p38/JNK Pathway Is Responsible for Embelin Induced Apoptosis in Lung Cancer Cells: Transitional Role of Reactive Oxygen Species." PMC3899364
• Wadhwa R, et al. "Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells." PMC4574062
• Jannotti-Passos LK, et al. "Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells." PMC5509148
• Yoo DY, et al. "XIAP inhibitor embelin induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells." PMC6472881
• Poojari R. "The Application of Embelin for Cancer Prevention and Therapy." PMC6017120
• Ali SA, et al. "Medicinal potential of embelin and its nanoformulations: An update on the molecular mechanism and various applications." PMC11366951
• Bhandari U, Jain N, Pillai KK. "Further Studies on Antioxidant Potential and Protection of Pancreatic β-Cells by Embelia ribes in Experimental Diabetes." PMC1880868
• Liu Y, et al. "Pharmacokinetic and Bioavailability Studies of Embelin after Intravenous and Oral Administration to Rats." PMC6446108
• Teklehaimanot GT, et al. "Evaluation of anthelmintic potential of the Ethiopian medicinal plant Embelia schimperi Vatke in vivo and in vitro against some intestinal parasites." PMC4470045
• Mahendran S, et al. "Plant Derived Phytocompound, Embelin in CNS Disorders: A Systematic Review." Frontiers in Pharmacology 8:76 (2017)
• Mohan P, et al. "Antidiabetic activity of Embelia ribes, embelin and its derivatives: A systematic review and meta-analysis." Biomedicine & Pharmacotherapy 86:195–204 (2017)
• Bhandari U, Ansari MN, Islam F. "Beneficial effect of Embelia ribes ethanolic extract on blood pressure and glycosylated hemoglobin in streptozotocin-induced diabetes in rats." Fitoterapia 79(5):325–329 (2008)
• Chitra M, Devi CS, Sukumar E. "Antibacterial activity of embelin." Fitoterapia 74(4):401–403 (2003)
• ScienceDirect Topics: Embelia ribes — Overview
• Importance of Embelia ribes: An Update. International Journal of Pharmaceutical Sciences and Research
• Krishnaswamy M, Purushothaman KK. "Antifertility properties of Embelia ribes: (embelin)." Indian J Exp Biol. 1980 Nov;18(11):1359–60. PMID: 7216303
• Saboo S, Ghadge T. "Embelin Novel Drug Molecule: A Review." Semantic Scholar
• Plants of the World Online — Embelia ribes Burm.f. Royal Botanic Gardens, Kew
• Embelia ribes — Grokipedia (Conservation Status, Taxonomy)
• Chitme HR, et al. "Pharmacological evaluation of embelin-chitosan nanoparticles as an antidiabetic agent." PMC9249157